OBJECTIVE: Cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC) have been recently reported with favourable oncological outcomes as treatment of @entity43 (EOC). The aim of this study was to demonstrate the feasibility of CRS+HIPEC with @entity900 and @entity1311 for the treatment of advanced EOC. METHODS: This is a prospective observational study of 54 @entity1 , from April 2007 to October 2013, with primary or recurrent @entity298 due to EOC. The mean age was 54.51  9.34. Thirty @entity1 (59%) had primary EOC, and 24 @entity1 (41%) had recurrent disease. RESULTS: Mean @entity3906 index was 10.11 (range, 0 to 28), complete cytoreduction (CC0) was achieved for 47 @entity1 (87%), @entity14105 for seven @entity1 (13%). @entity1 with suboptimal cytoreduction (CC2 and @entity14105 ) were not included in the study. The mean stay in ICU was 4.73  5.51 days and the mean hospitalization time was 24.0  10.03 days. We did not observe any intraoperative @entity204 . Seven @entity1 (13%) required additional operations. Three @entity1 (5.6%) died within 30 days from the procedure. Severe complications were seen in 19 @entity1 (35.2%). During the follow-up period, disease recurred in 33 @entity1 (61.1%); the median disease-free survival time was 12.46 months and the median overall survival time was 32.91 months. CONCLUSION: CRS+HIPEC with @entity900 and @entity1311 for advanced EOC is feasible with acceptable morbidity and mortality. Additional follow-up and further studies are needed to determine the effects of HIPEC on long term survival.

Hyperthermic intraperitoneal chemotherapy with XXXX and @entity1311 in advanced @entity43 : a multicenter prospective observational study.

@entity43 :: ('MESH:D010051', 'Disease') :: ['advanced epithelial ovarian cancer'] @entity1 :: ('9606', 'Species') :: ['Patients', 'patients'] @entity900 :: ('MESH:D002945', 'Chemical') :: ['cisplatin'] @entity1311 :: ('MESH:D017239', 'Chemical') :: ['paclitaxel'] @entity3906 :: ('MESH:D010534', 'Disease') :: ['peritoneal cancer'] @entity204 :: ('MESH:D003643', 'Disease') :: ['death'] @entity298 :: ('MESH:D010538', 'Disease') :: ['peritoneal carcinomatosis'] @entity14105 :: ('6358', 'Gene') :: ['CC3', 'CC1']
@entity900 :: (MESH:D002945,Chemical) :: ['cisplatin']
